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Cancer immunotherapy has emerged as a promising cancer treatment. However, the pre-
sence of immune-refractory tumor cells limits its clinical success by blocking amplification of
anti-tumor immunity. Previously, we found that immune selection by immunotherapy drives
the evolution of tumors toward multi-modal resistant and stem-like phenotypes via tran-
scription induction of AKT co-activator TCL1A by NANOG. Here, we report a crucial role of
HSP90A at the crossroads between NANOG-TCL1A axis and multi-aggressive properties of
immune-edited tumor cells by identifying HSP90AA1 as a NANOG transcriptional target.
Furthermore, we demonstrate that HSP90A potentiates AKT activation through TCL1A-
stabilization, thereby contributing to the multi-aggressive properties in NANOGhigh tumor
cells. Importantly, HSP90 inhibition sensitized immune-refractory tumor to adoptive T cell
transfer as well as PD-1 blockade, and re-invigorated the immune cycle of tumor-reactive
T cells. Our findings implicate that the HSP90A-TCL1A-AKT pathway ignited by NANOG is a
central molecular axis and a potential target for immune-refractory tumor.
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Harnessing the immune system to detect and eliminatetumor cells, cancer immunotherapy has emerged as apotentially powerful approach to cancer treatment1. Par-
ticularly, T cell-based therapeutic methods such as adoptive T cell
transfer (ACT) and immune checkpoint blockades (ICB) have
achieved tremendous progress in the field of cancer immu-
notherapy. However, despite the developing field’s potential to
revolutionize cancer treatment, the presence of immunother-
apeutic resistance limits its clinical application2. Among the
diverse causes of resistance to immunotherapy, the cancer
immunoediting theory has attracted attention as it can explain
the emergence of resistance to anti-tumor immunity3. Indeed,
there is increasing evidence that cancer immunoediting drives the
adaptation of tumor cells to host immune surveillance, thereby
contributing to a generation of cancer cells with better survival
advantages4. Furthermore, previous studies provide evidence that
preferential selection and subsequent expansion of a subset of
stem-like tumor cells with an undifferentiated phenotype con-
tribute to therapeutic resistance5–7. In this regard, we had found
that immune selection by immunotherapy drives the malignant
evolution of tumors toward multi-modal resistance and stem-like
phenotypes8. However, the potential link between the host
immune-intrinsic mechanisms (i.e., cancer immunoediting) and
the development of the malignant phenotypes of immune-
refractory tumor cells is not well understood.
Accumulating evidence indicate that the intrinsic properties of
tumors not only promote tumorigenesis but also interfere with
processes essential for an effective anti-tumor immune response,
such as T cell trafficking to tumors and T cell-mediated killing of
tumor cells9–11. It has been documented that tumor cell death by
T cells could lead to release of tumor antigens that prime sub-
sequent immune responses, known as the cancer-immunity
cycle12. Furthermore, recent studies provide evidence that T cell-
mediated killing of tumor cells is important for initiating or re-
invigorating the cancer-immunity cycle providing stimuli of
tumor neo-antigens to cytotoxic T lymphocytes (CTLs)13,14,
suggesting that intrinsic resistance of tumor cells to CTLs is a
critical obstacle to improving cancer immunotherapy. In this
regard, we have identified the transcription factor (TF) NANOG
as a key intrinsic factor that renders immune-edited tumor cells
impervious to cytotoxicity of T cells15,16. Therefore, NANOG, an
intrinsic factor of tumor cells, is a potential target to overcome the
immune-refractoriness by re-invigorating the immune cycle of
tumor-reactive T cells. In addition, we have also found that
NANOG confers multi-aggressive phenotypes to tumor cells
through transcriptional induction of TCL1A and subsequent
activation of the AKT-signaling pathway16. Notably, the inhibi-
tion of the NANOG signaling caused reversal of immune-
resistant phenotypes of the tumor cells and led to long-term
control of the disease16. This suggest that the strategies impeding
the NANOG–TCL1A–AKT axis may not only conquer the pro-
blem of immune escape but also that of multi-aggressive prop-
erties in immune-refractory cancer. Given that clinically available
pharmacologic inhibitors for NANOG have not been developed
yet, the identification of an additional targetable pathway is
needed to potentiate the efficacy of immunotherapy.
Heat shock protein 90 (HSP90), a molecular chaperone which
assists in protein folding to reach stability or degradation, is
known for its up-regulation in a wide range of cancers and
close association with a poor prognosis and resistance to che-
motherapies and radio-therapies17,18. In mammalian cells, HSP90
consists of four major subtypes: the inducible cytosolic isoforms
of HSP90A encoded by HSP90AA1, the constitutively expressed
HSP90B encoded by HSP90AB1, endoplasmic reticulum GRP94
encoded by HSP90B1, and mitochondrial TRAP-1 encoded by
TRAP1 (ref. 19). Of the HSP90s, HSP90A is overexpressed and
increases multi-malignant phenotypes including chemo-
resistance to cisplatin as well as metastatic potentials in various
types of cancers19–21. Although the importance of HSP90A as a
therapeutic target continues to grow, the potential relationship
between HSP90A and the multi-aggressive phenotypes conferred
by the NANOG–TL1A–AKT axis is yet to be studied extensively.
Here, we report that HSP90A is a clinically actionable target
for NANOG-mediated multi-aggressive properties of immune-
edited tumor cells. Mechanistically, transcriptional induction of
HSP90AA1 by NANOG leads to stabilization of TCL1A, which
contributes to subsequent activation of the AKT-signaling path-
way. Furthermore, we demonstrate that HSP90A inhibition with
AUY-922 renders tumor susceptible to T cell-based immu-
notherapy including ACT and anti-PD-1 therapy, and leads to
increase of the infiltration of tumor-reactive T cells via amplifi-
cation of anti-tumor immunity. Thus, we provide proof of
principle in a preclinical model that the inhibition of HSP90A
signaling is an appealing therapeutic strategy to incorporate with
various cancer therapeutic modalities, particularly an immune-
based modality, and overcome NANOGhigh immune-refractory
tumors.
Results
HSP90A confers multi-modal resistance and stem-like prop-
erty. Previously, we established a highly immune-resistant cervical
tumor cell line, CaSki P3, generated from its immune susceptible
parental cell line, CaSki P0, through three rounds of selection by
cognate CTLs22. Notably, the immune-edited tumor cells (termed
P3) were refractory to apoptotic death by multi-modality including
cisplatin, γ-radiation, as well as cognate CTLs, whereas the parental
cells (termed P0) remained sensitive to these8. To investigate
potential targetable pathways for restoring sensitivity to multi-
modalities in the immune-edited tumor cells, we performed 2D
protein electrophoresis and mass spectrometry in lysates derived
from P0 and P3 cells. From this analysis, we noted that HSP90A
was up-regulated in P3 cells compared to P0 cells (Supplementary
Fig. 1); this was then confirmed by Western blot (Fig. 1a). The
increased level of HSP90A protein in P3 cells was accompanied by
HSP90AA1 mRNA expression (Fig. 1b). HSP90AB1 and HSP90B1
encoding HSP90B and GRP-94, respectively, showed no significant
changes in mRNA expression from P0 and P3 cells (Supplementary
Fig. 2), further specifying HSP90A as our subjectable molecule. To
determine the roles of HSP90AA1 up-regulation in the immune-
resistant phenotype of P3 tumor cells, we silenced HSP90AA1 in P3
cells using three kinds of siRNAs: siHSP90AA1 #1, #2, or #3
(Supplementary Fig. 3a). Compared to siGFP-transfected control
cells, siHSP90AA1s-transfected P3 cells are more susceptible to
apoptosis induced by granzyme B, a key component in CTL-
mediated apoptosis (Supplementary Fig. 3b). Consistently, silencing
of HSP90AA1 reverses resistant phenotypes against to cognate
CTLs of P3 tumor cells (Fig. 1c), indicating a crucial role of
HSP90A in a tumor-intrinsic resistance to CTL. Besides immune
resistance, we reported the P3 cells have multi-modal resistance to
chemotherapy and radiotherapy, and cancer stem cell (CSC)-like
property8,23,24. Notably, siHSP90AA1 transfection re-sensitized P3
cells to chemotherapy and radiotherapy (Fig. 1d, e). In addition,
knockdown of HSP90AA1 in P3 cells decreased in vitro sphere-
forming capacity (Fig. 1f and Supplementary Fig. 4) and reduced
tumor-initiating property when transplanted into NOD/SCID mice
(Table 1), indicating that HSP90A is important for maintenance of
CSC-like properties in immune-edited P3 tumor cells. However, P0
cells transfected with siHSP90AA1 did not significantly alter the
susceptibility to CTL, cisplatin, and irradiation as well as sphere-
forming capacity (Fig. 1c–f). We next investigated whether, as with
CaSki P3 model, up-regulation of HSP90A is reproduced in other
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immune-edited tumor models, TC-1 P3 and MDA-MB231 P3,
which were generated from its immune-susceptible parental cell line
(TC-1 and MDA-MB231, respectively) through three rounds of
in vivo selection by cognate CTLs, respectively25,26. Consistent with
results from CaSki, we found that mRNA expression of Hsp90aa1
and HSP90AA1 was up-regulated in TC-1 and MDA-MB231 P3
cells, respectively, compared with their parental P0 cells (Supple-
mentary Fig. 5a). We also observed increase of HSP90A protein in
both murine and human tumor cells over the course of immu-
noediting (Supplementary Fig. 5b). Furthermore, we previously
reported the both TC-1 P3 and MDA-MB231 P3 cells have multi-
modal resistance to immunotherapy and chemotherapy, and CSC-
like property8,25. Notably, siHsp90aa1 or siHSP90AA1 transfection
re-sensitized P3 cells to immunotherapy and chemotherapy, and
reduced a stem-like phenotype (Supplementary Fig. 5c–e). Taken
together, our data demonstrated that HSP90A is up-regulated at the
transcriptional level during immunoediting, and contributes to
multi-modal resistance and CSC-like property of immune-edited
tumor cells.
HSP90AA1 is directly regulated by NANOG. We next
attempted to elucidate the underlying mechanism responsible for
HSP90AA1 up-regulation in immune-edited tumor. In this
regards, we previously demonstrated that NANOG is a key TF
driving multi-modal resistance and stem-like phenotype of the
immune-refractory tumor25. Therefore, we hypothesized that
NANOG might be responsible for transcriptional activation of
HSP90AA1 gene. Indeed, silencing of NANOG in P3 cells
resulted in decrease of HSP90A protein, which was accompanied
by decreased HSP90AA1 mRNA expression (Fig. 2a, b). Con-
versely, introduction of NANOG into P0 cells raised HSP90A
protein level and HSP90AA1 mRNA expression level (Fig. 2c, d).
Notably, NANOG WT profoundly increased levels of HSP90AA1
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Fig. 1 HSP90A is required for multi-aggressive properties of immune-edited tumor cells. a HSP90A protein level in CaSki P0 and P3 cells was
determined by Western blot. β-ACTIN was included as an internal loading control. Numbers below blot images indicate the expression as measured by fold
change. b HSP90AA1 mRNA level in CaSki P0 and P3 cells was determined by qRT-PCR. c–e CaSki P0 and P3 cells were transfected with siGFP or
siHSP90AA1-#1. c The frequency of apoptotic (active caspase-3+) cells in the MART-1 peptide pulsed cells after incubation with or without MART-1-
specific CTLs at a 1:1 ratio for 4 h was estimated by flow cytometry analysis. d and e Cells were treated with indicated concentrations of cisplatin d and
irradiation e. The percentage of viable cells was determined by trypan blue exclusion assay at 24 h after either cisplatin treatment or irradiation. *p < 0.01,
**p < 0.001, and ***p < 0.0001. f CaSki P0 and P3 cells were transfected with siGFP, siHSP90AA1-#1, or siHSP90AA1-#2. Sphere-forming capacity of the
cells in low-density suspension culture. All experiments were performed in triplicate. The p-values by two-tailed Student’s t test b or two-way ANOVA c–f
are indicated. NS, not significant. Data represent the mean ± SD. Source data are provided as a Source Data file.
Table 1 TIC frequency of CaSki P3-no insert, CaSki P3-shHSP90AA1 #1, and CaSki P3-shHSP90AA1 #2 cellsa.
CaSki P3 Number of tumors/number of injected animalsb TIC frequency (95% CI)c
105 104 103
No insert 6/6 6/6 4/6 1:910 (1/2545–1/326)
shHSP90AA1 #1 4/6 2/6 0/6 1:68,078* (1/166,908–1/27,768)
shHSP90AA1 #2 3/6 2/6 0/6 1:96,052** (1/249,831–1/36,929)
TIC tumor-initiating cell, CI confidence interval
*p= 4.6 × 10−10 and **p= 2.35 × 10−11 by pairwise tests
aTo estimate tumor initiating properties of these cells, in vivo limiting dilution transplantation assay was performed
bTumor cells of indicated number were subcutaneously injected into NOD/SCID mice (n= 6) and mice were scored for the presence of palpable tumors
cTIC frequency and 95% CI were calculated by using ELDA software program (http://bioinf.wehi.edu.au/software/elda/)
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previously characterized for its weak transcriptional activity16,
had no significant impact on both of HSP90AA1 mRNA and
HSP90A protein levels, indicating that NANOG regulates
HSP90AA1 expression through its transcriptional function
(Fig. 2e, f). To further elucidate the underlying mechanism by
which NANOG regulates HSP90AA1 transcription, we identified
the HSP90AA1 promoter region containing a putative NANOG-
binding site, suggesting the possibility that NANOG is a direct
transcriptional activator of HSP90AA1 (Fig. 2g). Luciferase
assays showed a significant increase in HSP90AA1 promoter
activity upon co-transfection with NANOG WT but not upon
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Fig. 2 HSP90AA1 expression is directly regulated by NANOG. a and b CaSki P3 cells were transfected with siRNA-targeting GFP or NANOG. a Levels of
NANOG and HSP90A protein were analyzed by Western blot. b HSP90AA1 mRNA expression was analyzed by qRT-PCR. c and d CaSki P0 cells were
stably transfected with empty vector (no insert) or NANOG. c Levels of NANOG and HSP90A protein were analyzed by Western blot. d HSP90AA1 mRNA
expression was analyzed by qRT-PCR. e and f HEK293 cells were transfected with empty vector (no insert), FLAG-NANOG wild type (NANOG WT) or
FLAG-NANOG mutant (NANOG MUT). e Levels of HSP90A and FLAG-NANOG proteins were proved by Western blot. f HSP90AA1 mRNA expression
was analyzed by qRT-PCR. g Diagram of HSP90AA1 promoter region (−1322 to +190) containing NANOG binding element. The arrows indicate ChIP
amplicon corresponding to −1048 to −899. h Luciferase assay in HEK293 cells transfected with the pGL3-HSP90AA1 WT or MUT plasmid, together no
insert, NANOG WT or NANOG MUT plasmids. i Chromatin immunoprecipitation assay was carried out using HEK293 cells transfected with FLAG-
NANOG. Cross-linked chromatin was immunoprecipitated with anti-FLAG antibodies. Immunoprecipitated DNAs were amplified with PCR primers specific
for the HSP90AA1 promoter region indicated above. Mouse IgG was used as a negative control. The input represents 2% of the total chromatin. j ChIP
assay was carried out using CaSki P0 and P3 cells. Cross-linked chromatin was immunoprecipitated with anti-NANOG antibodies. The value of ChIP data
represent relative ratio to the input. β-ACTIN was included as an internal loading control. Numbers below blot images indicate the expression as measured
by fold change a, c, and e. All experiments were performed in triplicate. The p-values by two-tailed Student’s t test b, d and j, one-way ANOVA f or two-
way ANOVA h are indicated. Data represent the mean ± SD. Source data are provided as a Source Data file.
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mutation of the NANOG-binding site in the HSP90AA1 pro-
moter region eliminated the promoter activation by NANOGWT
(Fig. 2h). Chromatin immunoprecipitation (ChIP) assays con-
firmed the direct binding of NANOG to the regulatory region of
HSP90AA1 gene (Fig. 2i), and also validated in the P0 and P3
cells, where we noted more NANOG occupancy in P3 cells,
relative to P0 cells (Fig. 2j). Altogether, these findings demon-
strate that NANOG up-regulates HSP90AA1 transcription by
directly binding to its promoter region.
We then wondered if HSP90A is required for promoting multi-
aggressive phenotypes that is mediated by NANOG. Consistently,
in the NANOG-overexpressing CaSki-NANOG cells, HSP90AA1
knockdown increased susceptibility to granzyme B, cisplatin, and
irradiation (Supplementary Fig. 6a–c) and decreased CSC-like
property (Supplementary Fig. 6d). These results indicate that
HSP90A plays a crucial role in the NANOG-mediated multi-
aggressive phenotypes including immune-refractoriness.
NANOG–HSP90A axis is conserved across various cancer
types. Having explored the molecular mechanism by which the
NANOG–HSP90A axis confers tumor-aggressive phenotypes, we
examined whether the NANOG–HSP90A axis is conserved across
multiple human cancer types. We observed a positive correlation
between NANOG and HSP90A protein levels in a variety of
human cancer cells (Fig. 3a, b). We then determined the clinical
relevance of the NANOG–HSP90A axis in human cancer patients.
Comparative transcriptome analysis using the cancer genome atlas
(TCGA) data reveals a positive correlation between NANOG and
HSP90AA1 mRNA levels in multiple human cancer types, such as
cholangiocarcinoma, testicular germ cell tumors, uveal melanoma
(Supplementary Fig. 7). Furthermore, we previously had reported
that high level of NANOG correlated with poor prognosis of
cervical carcinoma16. Thus, we evaluated HSP90A protein level by
immunohistochemistry in the same study population (Fig. 3d),
and found that HSP90A level increased during cervical carcinoma
progression (Supplementary Table 1). Upon the assessment
between the levels of NANOG and HSP90A in the cervical neo-
plasia specimens, HSP90A level was positively correlated with that
of NANOG (Fig. 3d). Importantly, patients with combined
NANOG+/HSP90A+ level was strongly associated with large-
sized tumor (Fig. 3e and Supplementary Fig. 8) and chemo-
radiation resistance (Fig. 3f and Supplementary Fig. 9) than those
with NANOG−/HSP90A− level. In addition, examining the rela-
tionship of combined NANOG+/HSP90A+ level with patient’s
survival outcomes, the Kaplan–Meier plots demonstrated that
NANOG+/HSP90A+ patients had shorter disease-free survival
than NANOG−/HSP90A− patients (Fig. 3g and Supplementary
Fig. 10). Consistently, NANOG+/HSP90A+ patients significantly
worse 10-year overall survival than NANOG−/HSP90A− patients
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Fig. 3 NANOG–HSP90A axis is conserved across various human cancer types. a Protein levels of NANOG and HSP90A in various human cancer cells
were determined by immunoblotting. This experiment was performed in triplicate. b Correlation between NANOG and HSP90A level normalized by β-
ACTIN level in various human cancer cells (Spearnan r= 0.7741, p= 0.0028). c Representative images of IHC staining of HSP90A in cervical tissue from
normal (n= 328), LGCIN (n= 65), HGCIN (n= 160), and cervical carcinoma (n= 151) patients. Scale bar shown is 250 µm. LGCIN low-grade CIN; HGCIN
high-grade CIN. d Correlation between NANOG and HSP90A in patients with cervical cancer (Spearnan r= 0.746, p < 0.001). e and f Combined level of
NANOG+/HSP90A+ was significantly associated with large-sized tumors e and chemoradiation resistance f in patients with cervical cancer.
Chemoradiation resistance was calculated only cases with available information of chemoradiation response. g Patients with NANOG+/HSP90A+ level
displayed worse disease-free survival (p= 0.007) than patients with NANOG−/HSP90A− level. Cut-off value of NANOG+ and HSP90A+ are 160 and 127,
respectively. The p-values were determined by Mann–Whitney U test e and f and Log-rank (Mantel–Cox) test g or spearman correlation (r) b and d. In the
box plots, the top and bottom edges of boxes indicate the first and third quartiles, respectively; the center lines indicate the medians; and the ends of
whiskers indicate the maximum and minimum values, respectively. Source data are provided as a Source Data file.
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(Supplementary Fig. 11). Furthermore, the level of NANOG+/
HSP90A+ was a significant risk factor for both disease-free sur-
vival (Supplementary Table 2) and overall survival (Supplemen-
tary Table 3). Collectively, these data indicate that the
NANOG–HSP90A axis is conserved across multiple human can-
cer types, highly related with therapeutic resistance and an
important prognostic factor in human cervical neoplasia.
HSP90A stabilizes TCL1A, thereby contributing AKT activa-
tion. Previously, we demonstrated that NANOG promotes
tumorigenicity and immune resistance of tumor cells through
AKT-dependent up-regulation of Cyclin A and MCL-1 (ref. 16).
Despite NANOG overexpression, knockdown of HSP90AA1
robustly dampened levels of pAKT, Cyclin A, and MCL-1
(Fig. 4a). Consistently, silencing of HSP90AA1 in P3 cells but not
in P0 cells (Supplementary Fig. 12a) and NANOG up-regulated
human cancer cells (Supplementary Fig. 12b) markedly reduced
the levels of them. Importantly, overexpression of constitutively
active AKT (CA-AKT) decreased the sensitivity of siHSP90AA1-
transfected CaSki-NANOG cells to CTLs and cisplatin (Supple-
mentary Fig. 13), suggesting that HSP90A plays a crucial role in
NANOG-mediated phenotypes by reinforcing the link between
NANOG and AKT-signaling pathway.
We next aimed to elucidate the role of HSP90A in NANOG-
induced activation of AKT signaling. In this regard, we previously
demonstrated that NANOG hyper-activates the AKT signaling
through transcriptional up-regulation of TCL1A, a co-activator of
AKT kinase27. Given the role of HSP90A as a chaperone in protein
stabilization, we questioned whether HSP90A affects protein levels
of AKT or TCL1A. The down-regulation of pAKT level upon
HSP90AA1 knockdown, however, was not accompanied with loss
of AKT protein (Fig. 4a and Supplementary Fig. 12). In contrast,
knockdown of HSP90AA1 in CaSki-NANOG cells significantly
decreased the levels of TCL1A protein (Fig. 4a). To assess whether
HSP90A affects TCL1A stability, we measured the half-life of
TCL1A protein upon HSP90AA1 knockdown by performing a
cycloheximide-chase assay. Notably, the half-life of endogenous
TCL1A protein in siHSP90AA1-transfected CaSki-NANOG cells
decreased, compared with those of the siGFP-transfected cells
(Fig. 4b). In addition, treatment of MG132 blocked TCL1A protein
down-regulation upon HSP90AA1 knockdown (Fig. 4c), indicating
the proteasome-mediated degradation of TCL1A protein. Since
poly-ubiquitination is required for proteasome-dependent protein
degradation, we examined whether HSP90A affects ubiquitination
of TCL1A protein. As shown in Fig. 4d, ubiquitination of TCL1A
was significantly increased by HSP90AA1 knockdown. Notably, we
noted that decreased pAKT level and increased susceptibility to
CTLs and cisplatin after HSP90AA1 knockdown in CaSki-
NANOG cells were reversed upon restoration of TCL1A expression
(Fig. 4e and Supplementary Fig. 14). These results suggest that
HSP90A-mediated TCL1A stabilization is important for NANOG-
induced AKT activation as well as multi-modal resistance.
We then assessed the effect of HSP90AA1 overexpression on
CaSki P0 cells. Overexpression of HSP90AA1 in P0 cells increased
TCL1A stability and pAKT level (Supplementary Fig. 15a and b).
Importantly, HSP90AA1-transfected P0 cells were more resistant to
apoptosis induced by CTLs, compared to empty vector-transfected
P0 cells (Supplementary Fig. 15c), indicating that HSP90AA1
expression by itself is sufficient to confer resistance to CTLs. Taken
together, our data indicate that HSP90A leads to activation of AKT
signaling through TCL1A stabilization, and thus contributes to
multi-modal resistance of tumor cells.
Previously, it was reported that chemical inhibition of HSP90
promotes the proteosomal degradation of HSP90 client proteins by
inhibiting its chaperone association28. Therefore, we determined
whether TCL1A has chaperone association with HSP90A, as a client
protein. Notably, TCL1A protein exhibited chaperone associated
with HSP90A (Fig. 4f), which was disrupted after treatment with
AUY922, the HSP90A inhibitor (Fig. 4g). Consistently, treatment
with AUY922 also promotes ubiquitin-dependent proteosomal
degradation of TCL1A protein (Fig. 4h, i). Furthermore, HSP90A
level was positively correlated with TCL1A level in the cervical
neoplasia specimens (Supplementary Fig. 16a) and patients with
combined HSP90A+/TCL1A+ level exhibited a tendency of worse
disease-free survival (Supplementary Fig. 16b–e). Thus, our results
demonstrate that TCL1A is a client protein of HSP90A, and that
HSP90A’s direct binding leads to it stabilization, thereby contribut-
ing to AKT activation in NANOGhigh tumor cells.
HSP90A is a therapeutic target for NANOGhigh tumor cells. To
verify the biochemical effects of HSP90A–TCL1A–AKT axis in
diverse types of human cancer cells, we further selected two
NANOG up-regulated human cancer cells SiHa and HCT116,
and immune-edited MDA-MB231 P3 (ref. 25). Inhibition of
HSP90A with AUY922 robustly dampened AKT phosphorylation
level and expression of the effectors in NANOG signaling, such as
MCL-1, Cyclin A, and TCL1A across all tested cancer cells
(Fig. 5a). Furthermore, AUY922-treated tumor cells were more
susceptible to multi-modal therapy and showed diminished
sphere-shaping capacities compared with DMSO-treated tumor
cells (Fig. 5b–e). These results demonstrate that the functional
and biochemical properties of the HSP90A–TCL1A–AKT axis are
conserved across multiple types of cancer cells and that HSP90A
is an actionable target for controlling NANOGhigh human tumor
cells.
HSP90A inhibition reverses resistance to ACT. Given our
observations in vitro, we reasoned that in vivo administration of
AUY-922 should reverse resistance to T cell-base immunother-
apy. To test this possibility, we treated MART1+ MDA-MB231
P3-bearing NOD-SCID mice with MART-1-specific CTLs along
with AUY-922 (Fig. 6a). While immunotherapy alone had no
effect on tumor growth, dual therapy with E7-specific CTLs and
AUY-922 retarded tumor growth (Fig. 6b, c) and prolonged
survival of the mice (Fig. 6d). Consistent with our in vitro results,
we observed reduced levels of TCL-1, pAKT, MCL-1, and Cyclin
A in tumor tissue from AUY922-treated mice compared with that
from un-treated mice (Fig. 6e). In addition, measurements by
Ki67 staining demonstrated that AUY-922-treated tumors con-
tained fewer proliferating cells than PBS-treated tumors, as this
was unaffected by the adoptive transfer of CTL (Fig. 6f). Although
we observed a slight, but not statistically significant decrease in
the frequency of antigen-specific CTLs in the tumors of AUY-
922-treated mice compared with those in PBS-treated mice, the
overall cytotoxic effect of these CTLs was greater after treatment
of AUY-922 relative to that than PBS control, as indicated by the
percentage of apoptotic tumor cells (Fig. 6g, h). Taken together,
we conclude that inhibition of HSP90A can incapacitate the
immune resistance of immune-edited tumor cells and represents
an attractive strategy for the control of human cancer, as a
synergistically, as part of a T cell-mediated immunotherapy.
HSP90AA1 is associated with poor response to ICB. Based on
our observations, we further questioned that NANOG–HSP90A
axis may also contribute poor response to ICB. To determine the
clinical relevance of NANOG–HSP90A axis, we used the tran-
scriptome data from melanoma patients classified as responders
(R) or non-responders (NR) to anti-PD-1 therapy29. From the
comparative transcriptome analysis of differentially expressed
genes (DEGs) in two patient groups (Fig. 7a), we found that only
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Fig. 4 HSP90A contributes to NANOG-induced AKT activation through TCL1A-stabilization. a–e CaSki-NANOG cells were transfected with siGFP or
siHSP90AA1-#1. a Levels of HSP90A, TCL1A, pAKT, AKT, MCL1, and Cyclin A were analyzed by immunoblotting. Graph depicts the experimental
quantitation based on at least three independent experiments. **p < 0.001, ***p < 0.0001 by two-tailed Student’s t test. NS not significant. b The cells were
treated with cycloheximide (CHX) for the indicated times. Cell lysates were subjected to immunoblotting with anti-TCL1A antibodies. Graph represents the
means ± SD of three quantified data, after normalization to the corresponding β‐ACTIN level. c The cells were treated with or without MG132 (10 μM) for
8 h. Cell lysates were subjected to immunoblotting with anti-HSP90A and anti-TCL1A antibodies. d The cells, transfected with indicated plasmids, were
treated with MG132. Cell lysates were immunoprecipitated with anti-Myc antibody, and immunoblotted with the anti-HA antibody. The input represents
5% of total proteins. e siHSP90AA1-transfected CaSki-NANOG cells were transfected with TCL1A-Myc constructs. Levels of HSP90A, TCL1A, pAKT, and
AKT were analyzed by immunoblotting. f HEK293 cells were transfected with TCL1A-Myc. g TCL1A-Myc-transfected HEK293 cells were treated with
DMSO or AUY-922 as indicated. f and g Cell lysates were immunoprecipitated with anti-Myc antibody, followed by western blotting using anti-Myc and
anti-HSP90A antibodies. h HEK293 cells, transfected with indicated plasmids, were treated with or without MG132 (10 μM) for 8 h and were subjected to
immunoblotting with anti-Myc and anti-HSP90A antibodies. Graph depicts the experimental quantitation of TCL1A protein level based on at least three
independent experiments. The p-value by one-way ANOVA is indicated. i CaSki-NANOG cells were transfected with HA-Ub or TCL1A-Myc constructs and
then were treated with DMSO or AUY-922 as indicated. Cell lysates were immunoprecipitated with anti-Myc antibody, and immunoblotted with the anti-
HA antibody. The input represents 5% of total proteins. Numbers below blot images indicate the expression as measured by fold change a–c, e and h. All
experiments were performed in triplicate. Data represent the mean ± SD a and h. Source data are provided as a Source Data file.
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the HSP90AA1 expression level among the four genes of the
HSP90 family (HSP90AA1, HSP90AB1, HSP90B1, TRAP1) was
significantly higher in NR compared with R (Fig. 7b).
It has been reported that multi-gene signature is associated
with clinical efficacy of PD-1 blockade30. To gain insights into
NANOG as a TF responsible for response to anti-PD-1 therapy,
we performed TF analysis using up-regulated or down-regulated
DEGs in NR relative to R to anti-PD-1 therapy. From this
analysis, we noted that many of the up-regulated DEGs in NR
were directly linked to NANOG (Fig. 7c). On the other hand,
genes regulated by IRF8, a TF in the interferon gamma (IFN-γ)-
signaling pathway, were down-regulated in NR to anti-PD-1
therapy (Supplementary Fig. 17a and b). This finding is consistent
with recent studies demonstrating that an IFN-γ signature was
found to be differentially down-expressed in the pretreatment
tumor biopsies from non-responding patients31–33.
To validate preliminary NANOG-responsive genes from this
analysis, we further performed a complementary analysis
followed by filtering to include only genes that have been
previously identified as responding to NANOG34–38. Subse-
quently, we acquired the refined NANOG-responsive six
genes (FGFBP1, SPESP1, HMGA2, PERP, FGF1, and DKK1).
To quantify the expression of NANOG-responsive genes, we
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Fig. 5 HSP90A inhibition reduces multi-aggressive properties of NANOGhigh tumor cells. a–e CaSki P3, MDA-MB231 P3, SiHa, and HCT116 cells were
treated with DMSO or AUY-922. a Levels of HSP90A, TCL1A, pAKT, AKT, MCL1, Cyclin A, and β‐ACTIN were proved by Western blot. β-ACTIN was
included as an internal loading control. Numbers below blot images indicate the expression as measured by fold change. Graph depicts the experimental
quantitation based on at least three independent experiments. b Flow cytometry analysis of the frequency of apoptotic (active caspase-3+) cells in the cells
after intracellular delivery of granzyme B for 4 h. c and d Cells were treated with indicated concentrations of cisplatin c and irradiation d. The percentage of
viable cells was determined by trypan blue exclusion assay at 24 h after either drug challenge or irradiation. e Sphere-forming capacity of the cells in low-
density suspension culture. All experiments were performed in triplicate. The p-value by two-tailed Student’s t test a, one-way ANOVA b and e or two-way
ANOVA c and d are indicated. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Data represent the mean ± SD. Source data are provided as a Source
Data file.
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expression level of the NANOG-responsive genes was signifi-
cantly higher in NR compared with R to anti-PD-1 therapy
(Fig. 7d). Furthermore, we also found a strong correlation
between NANOG-responsive genes and HSP90AA1 expression in
NR (Fig. 7e, f).
We next examined the clinical relevance of the NANOG–HSP90A
axis. Kaplan–Meier plots demonstrated that patients with high levels
of NANOG-responsive genes or HSP90AA1 displayed worse overall
survival rate (Fig. 7g). Furthermore, patients with high expression
levels of both NANOG-responsive genes and HSP90AA1 showed
significantly worse overall survival rate (Fig. 7g). Taken together, our
data suggest that NANOG–HSP90AA1 axis could be a biomarker in
predicting response and clinical outcome to anti-PD-1 therapy, and
provide a rationale for the clinical use of HSP90A inhibitors.
HSP90A inhibition renders tumor susceptible to PD-1 block-
ade. We next assessed whether NANOG–HSP90A axis would be
also responsible for refractoriness to ICB therapy. To do this, we
examined levels of NANOG and HSP90A in a number of
mouse cancer cell lines, and then selected a murine tumor cell line
having high level of both NANOG and HSP90A, B16-F10, which
is relatively resistant to ICB therapy39 (Supplementary Fig. 18a).
Knockdown of NANOG or inhibition of HSP90A with AUY-922
in B16-F10 cells substantially decreased the levels of TCL1A,
pAKT, MCL1, and Cyclin A (Supplementary Fig. 18b and c).
Consistently, the AUY-922-treated tumor cells were more sus-
ceptible to apoptosis induced by granzyme B compared to
DMSO-treated tumor cells (Supplementary Fig. 18d). These data
indicate that biochemical and functional properties of the
NANOG–HSP90A–TCL1A axis are conserved in the immune-
refractory murine tumor model.
Responses to ICB therapy in patients is predictable by pre-
existing CD8+ T cells that can most robustly be measured via
expression of CD8+ T cell signature11,40. Interestingly, we found
that level of NANOG-responsive genes and HSP90AA1 within
tumor inversely correlated with T cell infiltration in various
cancer patients from TCGA (Supplementary Fig. 19), suggesting
NANOG–HSP90A axis in tumor cells induces ICB therapeutic
resistance. To investigate whether NANOG–HSP90A axis is
responsible for resistance to anti-PD-1 therapy in vivo, we
treated NANOG/HSP90Ahigh (B16F10 or MC38) or NANOG/
HSP90Alow (B16F1 or CT26) tumor-bearing mice with anti-PD-
1 antibody along with AUY-922 (Fig. 8 and Supplementary
Fig. 20). Anti-PD-1 antibody alone treatment showed a
remarkable therapeutic effect in NANOG/HSP90Alow (B16F1
and CT26) tumor-bearing mice (Supplementary Fig. 20b and c).
In contrast, in NANOG/HSP90Ahigh (B16F10 or MC38) tumor-
bearing mice, while anti-PD-1 antibody alone treatment had no
effect on tumor growth, the combination treatment with anti-
PD-1 antibody and AUY-922 retarded tumor growth (Fig. 8b, c
and Supplementary Fig. 20d) and prolonged survival of
tumor-bearing mice (Fig. 8d). These results suggest that
NANOG–HSP90A axis could be responsible for resistance to
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Fig. 6 HSP90A inhibition reverses the resistant phenotype to adoptive T cell therapy. a Schematic of the therapy regimen in NOD-SCID mice implanted
with MDA-MB231 P3 cells. b Tumor growth, c mass (at 21 days after challenge), and d survival of mice inoculated with MDA-MB231 P3 treated with the
indicated reagents. e Western blot analysis of TCL1A, pAKT, AKT, MCL1, Cyclin A protein in mice administered with PBS or AUY-922, with or without
adoptive transfer of MART-1-specific CTLs. β-ACTIN was included as an internal loading control. Numbers below blot images indicate the expression as
measured by fold change. f The proliferation index of cells inside the tumor, as measured by the mean fluorescence intensity of Ki67 staining. g Flow
cytometric analysis of the frequency of CFSE-labeled MART-1-specific CTL in the tumors of mice that received adoptive transfer. h The frequency of
apoptotic cells in the tumors of PBS-treated or AUY-922-treated mice, with or without adoptive transfer of MART-1–specific CTL. For in vivo experiments,
five mice from each group were used. The p-value by two-way ANOVA b, one-way ANOVA c, f and h, Log-rank (Mantel–Cox) test d or two-tailed
Student’s t test g are indicated. Data represent the mean ± SD. Source data are provided as a Source Data file.
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NANOG–HSP90A axis-mediated resistant phenotype of tumor
cells to immunotherapy.
Accumulating evidence suggest that tumor cell death in anti-
tumor therapy could lead to release of tumor antigens that
prime subsequent auto-loop of anti-tumor immune responses
(known as the cancer-immunity cycle)12–14. We found that the
percentage of apoptotic tumor cells was increased in the
combination treatment compared with either treatment alone
(Fig. 8e). Therefore, we postulated that HSP90A inhibition
along with anti-PD-1 treatments inflames tumor immune-
environments by reversing resistance of immune-refractory
tumor cells to T-cell-mediated cytotoxicity. Indeed, the number
of overall CD8+ T cells and tumor-reactive CD8+ T cells
making granzyme B were significantly higher in the combina-
tion treatment group compared to the other treatment group-
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Fig. 7 NANOG–HSP90AA1 axis is associated with poor response to PD-1 blockade therapy. a Volcano plot shows the DEGs between non-responder and
responder to PD-1 blockade therapy. Colors of dots indicate significantly (black) or non‐significantly (gray) altered genes in above or below the horizontal
dashed line at p= 0.05. Red dot indicates the HSP90AA1 gene. Vertical dashed lines indicate a fold change cut off (1.5FC). The p-values were determined
by two-tailed test. b Comparisons of expressions levels of HSP90AA1, HSP90AB1, HSP90B1, and TRAP1 in responder (R, n= 10) and non-responder (NR,
n= 39). c TF analysis of up-regulated DEGs in non-responders relative to responders to anti-PD-1 therapy. Each dot represents one TF which has
transcription factor motifs enriched in DEGs. Vertical dashed line indicates p-value cutoffs at the 0.05 level. d Comparisons of expression level of NANOG-
responsive genes in the responder (R, n= 10) and non-responder (NR, n= 39). e Correlation between expression level of NANOG-responsive genes and
HSP90AA1 in non-responder (Spearman’s R= 0.3846, p= 0.0156). f Comparisons of HSP90AA1 expression in non-responders with low levels (Low n=
18) and high levels (High, n= 21) of NANOG-responsive genes. Error bars represent standard deviations from the mean. The p-value by unpaired t-test are
indicated. g Kaplan–Meier analysis of overall survival (calculated as months to death or months to last follow-up) and median expression value cutoffs for
expression level of NANOG-responsive genes (left, NANOG.high >median; NANOG.low <median, p= 0.0396) and HSP90AA1 (HSP90AA1high > median;
HSP90AA1low <median, p= 0.0265, middle) and combined each (p= 0.008, right). The p-values were determined by Gehan–Breslow–Wilcoxon test. In
the box plots, the top and bottom edges of boxes indicate the first and third quartiles, respectively; the center lines indicate the medians; and the ends of
whiskers indicate the maximum and minimum values, respectively. Source data are provided as a Source Data file.
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CD8+ T cells could be enhanced by the combined treatment. To
test whether the generation of tumor-reactive T cells was
affected by dual treatment, we isolated cells from tumor, drain
lymph node, or spleen of mice received therapy, stimulated
ex vivo with either DMSO (control) or gp100 (B16-F10 tumor-
associated antigen), and then assessed IFN-γ producing CD8+
T cells. Notably, IFN-γ-positive CD8+ T cells following
stimulation with gp100 were increased in combination treat-
ment group compared to the other treatment groups (Fig. 8h).
Taken together, our results demonstrate that the HSP90A
inhibition enhances response to ICB therapy by reversing
immune resistance of tumor cells to CTL killing, which switches
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Fig. 8 HSP90A inhibition renders the tumor susceptible to anti-PD-1-mediated anti-tumor immunity. a Schematic of the therapy regimen in mice
implanted with B16F10 cells. b–h Tumor-bearing mice administered vehicle or AUY-922, with or without treatment of PD-1 antibody. b Tumor growth and
c tumor mass in mice at 19 days after challenge. d Survival of mice inoculated with B16F10 cells treated with the indicated reagents. e The frequency of
apoptotic cells in the tumors of vehicle-treated or AUY-922-treated mice, with or without anti-PD-1 treatment. f Flow cytometry profiles of tumor-
inflitrating CD3+ and CD8+ T cells. g The ratio of Granzyme B+ to tumor-inflitrating CD3+ CD8+ T cells. h Quantification of antigen-specific CTLs in
tumor (left), drain lymph node (middle), or spleen (right) derived from the tumor-bearing mice. i Schematic interpretation of the molecular mechanism by
which NANOG–HSP90A–TCL1A axis promotes multi-modal-resistance and stem-like property of immune-refractory tumor cells. Numbers below blots
indicate the expression as measured by fold change. For in vivo experiments, 10 mice from each group were used. The p-value by one-way ANOVA c and
e–h or Log-rank (Mantel–Cox) test d is indicated. Data represent the mean ± SD. Source data are provided as a Source Data file.
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Discussion
Immunoediting of tumor cells can provoke multi-modal resis-
tance to chemotherapy, radiotherapy, as well as immunotherapy
and promote a stem-like phenotype. In the process, NANOG
mediates the pro-survival and stem-like phenotype of the
immune-edited tumor cells through the AKT pathway. Thus,
strategies impeding the NANOG-signaling pathway may not only
conquer the problem of therapeutic resistance but also that of the
stem-like state in cancer. In this study, we demonstrated the
crucial role of HSP90A at the crossroads between NANOG sig-
naling and the multi-aggressive properties of immune-edited
tumor cells by identifying HSP90AA1 as a NANOG transcrip-
tional target. In this vein, the NANOG–HSP90A axis was widely
conserved in various TCGA cohorts and tumor cells derived from
multiple types of human cancer, as well as in tumor tissue from
patients with cervical cancer. Furthermore, levels of NANOG and
HSP90A within the tumor correlated strongly with disease pro-
gression and survival in cancer patients, indicating that the
expression status of HSP90A (either alone or in conjunction with
NANOG) within tumor tissue may serve as an excellent prog-
nostic marker.
As the NANOG–HSP90A axis has been implicated as a central
channel in the development of immune-resistant phenotypes, we
believe that inhibition of HSP90A may be an effective strategy to
control immune-refractory tumor cells. Indeed, HSP90A inhi-
bition has received attention for therapeutic purposes in solid
tumors and hematologic malignancies, even though it has shown
limited responses as a single agent in cancer patients. In this
study, we provide rational for combination of HSP90A inhibition
with T cell-mediated immunotherapy. Notably, HSP90A inhi-
bition with AUY-922 in tumor cells following immunoediting
restores sensitivity to lysis by CTLs and effectively controls
tumor growth in mice transferred with tumor-specific CTLs.
Furthermore, AUY-922 treatment enhances anti-PD-1 therapy
in B16F10 tumors, which have no significant response to anti-
PD-1 therapy. To extend our findings to clinical relevance, we
examined clinical samples from patients treated with anti-PD-1
antibody and noted an association between increased expression
of HSP90AA1 and non-response to anti-PD-1 therapy, sug-
gesting the crucial role of HSP90A in resistance to anti-PD-1
therapy as well as ACT.
Given the crucial role of HSP90A in intrinsic resistance to
CTLs, it is intriguing, and perhaps counterintuitive, that the
combination of AUY-922 and anti-PD-1 therapy further increase
trafficking of effector CD8+ T cells to tumors. Nonetheless, it has
been documented that tumor cell death in anti-tumor therapy
may lead to release of tumor antigens that prime subsequent
immune responses, known as the cancer-immunity cycle. The
cancer-immunity cycle tightly modulates immune phenotypes in
the tumor microenvironment41,42. All human cancers can be
grouped into two immune profiles, non-T cell inflamed and T cell
inflamed, depending on their immune phenotypes43. Accumu-
lating evidence suggest that disruption of one or more steps of the
cancer-immunity cycle may trigger the switch of immune phe-
notypes from T cell-inflamed tumor to non-T cell-inflamed
tumor10,42–45. Particularly, T cell-mediated killing of tumor cells
is important for initiating or re-invigorating the cancer-immunity
cycle by providing stimuli of tumor antigens including neo-
antigens to cognate T cells13,14. These studies suggest that
intrinsic resistance to CTLs could be a crucial cause to disrupt a
self-sustaining cancer-immunity cycle that determines immune
phenotypes. In light of this, our results demonstrate that HSP90A
inhibition could induce T cell-inflamed immune phenotypes by
reversing resistance to T-cell-mediated cytotoxicity in tumor
microenvironments, indicating the re-invigoration of the cancer-
immunity cycle.
Notably, HSP90A is important in maintenance of structural
integrity for its client proteins, thereby regulating a variety of
cellular processes18. In this regard, many of its client proteins are
known oncogenic drivers that can regulate tumor intrinsic
pathways, some of which may provide a route of interference in
response to immunotherapy46. Here, we discovered that
HSPA90A plays a crucial role in NANOG-mediated phenotypes
by reinforcing the link between NANOG and the AKT-signaling
pathway. In the course of elucidating HSP90A’s function in
NANOG signaling, we identified TCL1A as a client protein of
HSP90A. With the reports on how TCL1A activates the AKT
pathway as an adaptor that facilitates AKT dimerization
and cross phosphorylation27, we found that NANOG coopera-
tively reinforces TCL1A-AKT signaling, a key pathway in multi-
aggressiveness of immune-refractory tumor cells by up-regulation
of HSP90A (Fig. 8i). Although AKT has been identified as one of
HSP90’s client proteins47, it seems that dampening of the AKT
signal through HSP90A inhibition is not due to the loss of AKT
proteins. In our present study, we demonstrate that HSP90A
potentiates the NANOG-induced AKT activation through
TCL1A stabilization, thereby contributing to the NANOG-
mediated multi-malignant phenotypes.
It should be noted that the roles of extracellular HSP90A
in mediating tumor progression or promoting anti-tumor
immunity remains a complex and controversial matter. Nota-
bly, it is obvious that surface-localized or extracellularly released
HSP90 in situations not involving cell death might also benefit
the tumor48. For instance, extracellular HSP90A plays a role in
sustaining cancer cell motility, invasion, and metastatic
spread20,49–51. Nevertheless, it has been well documented that cell
surface and extracellular HSPs are most commonly associated
with induction of immune responses52. Indeed, surface exposure
of HSP90 induced by antitumor drugs on dying myeloma cells
promotes the induction of specific immune responses to
tumor cells52. In light of this, we postulate that intracellular
HSP90A could serve as extracellular HSPs, potentially leading to
anti-tumor immunity, if the tumor cells are dying or exposed to
cellular stress in tumor microenvironment.
In general, HSP90s act as molecular chaperones in concert with
other chaperones including HSP70 to provide maturation and
folding of their client proteins53. Indeed, HSP90 and HSP70 have
been linked to cancer resistance to stress-mediated apoptotic
signals54. Paradoxically, HSP90 inhibition with AUY-922 con-
sistently leads to up-regulation of HSP70 inside and outside of
tumor cells55. The induction of HSP70 may ultimately limit the
efficacy of HSP90 inhibitors under certain circumstances54.
Nonetheless, it has been well documented that tumor-derived
extracellular HSP70 could contribute to activation of antitumor
immunity by acting as damage-associated molecular pattern
(DAMP) or chemokine56,57. In addition, cell surface-bound
HSP70 mediates granzyme B-dependent apoptosis by specific
binding and uptake of granzyme B58. Therefore, it will be
important in future studies to assess involvement of other cha-
perones including HSP70 in promoting anti-tumor immunity to
AUY922.
Altogether, we propose that NANOG+ cancer cells enriched by
immunoediting drive preferential expression of HSP90AA1 via
transcriptional regulation and undergo HSP90A accumulation
in tumor cells. Through this process, HSP90A potentiates
NANOG-induced AKT activation through TCL1A stabilization,
solidifying the NANOG-mediated multi-aggressive phenotypes of
immune-refractory tumors. Furthermore, we demonstrate that
inhibition of HSP90A with AUY-922 enhances tumor suscept-
ibility to T-cell-based immunotherapy by re-invigorating the
cancer-immunity cycle. Therefore, our data provide evidence that
the inhibition of HSP90A may be a promising strategy that will
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help combat NANOG+ immune-refractory tumors, particularly
in regard to immune-based cancer therapy.
Methods
Mice. Six- to eight-week-old female NOD/SCID or C57BL/6 mice were purchased
from Central Lab. Animal Inc. (Seoul, Korea). All mice were maintained and
handled under the protocol approved by the Korea University Institutional Animal
Care and Use Committee (KOREA-2017-0141). All animal procedures were per-
formed in accordance with recommendations for the proper use and care of
laboratory animals.
siRNA and shRNA constructs. Synthetic small interfering RNAs (siRNAs) spe-
cific for GFP, HSP90AA1, and NANOG were purchased from Bioneer (Korea);
Non-specific GFP (green fluorescent protein), 5′-GCAUCAAGGUGAACUUC
AA-3′ (sense), 5′-UUGAAGUUCACCUUGAUGC-3′ (antisense); HSP90AA1#1,
5′-CACCAAACAUAACGAUGAU-3′ (sense), 5′-AUCAUCGUUAUGUUUGG
UG-3′ (antisense); HSP90AA1#2, 5′-UGAAGGAGAUGACGACACA-3′ (sense),
5′-UGUGUCGUCAUCUCCUUCA-3′ (antisense); HSP90AA1#3, 5′-GGCACCU
GUUAACUGGUACCA-3′ (sense), 5′-UGGUACCAGUUAACAGGUGCC-3′
(antisense); NANOG, 5′-GCAACCAGACCUGGAACAA-3′ (sense), 5′-UUGUU
CCAGGUCUGGUUGC-3′ (antisense). For stable knockdown of HSP90AA1, the
following complementary oligonucleotides were annealed and cloned into BamHI/








Cell lines and reagents. CaSki, MDA-MB231, SiHa, HCT116, and HEK293 cell
lines were purchased from American Type Culture Collection (ATCC, Manassas,
VA, USA). All cell lines were obtained between 2010 and 2014, and tested for
mycoplasma using Mycoplasma Detection Kit (Thermo Fisher Scientific, San Jose,
CA, USA). The identities of cell lines were confirmed by short tandem repeat (STR)
profiling by IDEXX Laboratories Inc. and used within 6 months for testing.
Generation and maintenance of the immune-edited CaSki P3 (ref. 22) and MDA-
MB P3 (ref. 25) cell lines have been previously described. CaSki-NANOG cell line
has been previously described25. For generation of stable HSP90AA1 knockdown-
CaSki P3 cell lines, pSilencer-shHSP90AA1#1, -shHSP90AA1#2, or empty vector
(no insert) were transfected into CaSki P3 cells. Stably transfected cells were
selected with puromycin (0.7 μg mL−1). All cells were grown at 37 °C in a 5% CO2
incubator/humidified chamber. Cisplatin and AUY-922 were purchased from
Selleckchem (Huston, TX, USA).
DNA constructs and site-directed mutagenesis. The pMSCV-NANOG WT and
MUT plasmids have been described previously16. pME18-myc/TCL1 was kindly
provided by Dr. Masayuki Noguchi of Hokkaido University27. To generate the
pGL3-HSP90AA1 promoter, the promoter region of the HSP90AA1 gene was
isolated by PCR from genomic DNA extracted from CaSki cells using the following
primer set, 5′-TTCTCGAGTTCACACGCTCTTAAGGGGG-3′ (forward) and 5′-
CCAAGCTTCTTGGCTAAGTGACCGCACA-3′ (reverse). The PCR products
were digested with XhoI and HindIII and subcloned into the XhoI/HindIII
restriction sites of the pGL3-Basic vector (Promega). Site-directed mutagenesis was
performed using a QuickChange XL Site-directed Mutagenesis kit (Stratagene, San
Diego, CA, USA) according to the manufacturer’s instructions. To create mutations
in the NANOG-binding sites of the HSP90AA1 promoter region, the following
primer sets were used: for pGL3-HSP90AA1 promoter-NANOG MUT, 5′-CAAG
ATATCCGAAAATTCCCGGGTAGAAACTGGCTTTTCC-3′ (sense) and 5′-TGG
AAAAGCCAGTTTCTACCCGGGAATTTTCGGATATCTTG-3′ (antisense).
Mutations were verified by DNA sequencing.
Real-time quantitative RT-PCR. Total RNA was isolated using RNeasy Micro kit
(Qiagen), and the cDNAs were synthesized by reverse transcriptase (RT) using
iScript cDNA synthesis kit (Bio-Rad), according to the manufacture’ recommended
protocol. Real-time quantitative PCR was performed using iQ SYBR Green super
mix (Bio-Rad) with the specific primers on a CFX96 real-time PCR detection
system. All real-time quantitative PCR experiments were performed in triplicate
and quantification cycle (Cq) values were determined using Bio-Rad CFX96
Manager 3.0 software. Relative quantifications of the mRNA levels was
performed using the comparative Ct method with β-ACTIN as the reference gene.
The sequences of primers used for real-time PCR experiments are shown in
Supplementary Table 4.
Western blot analysis. Lysate extracted from a total of 1 × 105 cells was used to
perform Western blot. Primary antibodies against HSP90A (PA3-013, Thermo
Fisher Scientific, Fremont, CA), AKT (#9272, Cell Signaling Technology, Danvers,
MA), phospho-AKT (S473) (#9271, Cell Signaling Technology), MCL1 (sc-819,
Santa Cruz Biotechnology, CA), Cyclin A (sc-239, Santa Cruz Biotechnology),
NANOG (A300-397A, Bethyl Laboratories, Montgomery, TX), FLAG (M185-3L,
MBL, Nagoya, Japan), Myc (M192-3, MBL), HA (sc-805, Santa Cruz Biotechnol-
ogy), and β-ACTIN (M177-3, MBL) were used. Western blotting was followed by
the appropriate secondary antibodies conjugated with horseradish peroxidase.
Immunoreactive bands were developed with the chemiluminescence ECL detection
system (Elpis Biotech, Daejeon, Korea), and signals were detected using a lumi-
nescent image analyzer (LAS-4000 Mini, Fujifilm, Tokyo).
ChIP and quantitative ChIP (qChIP) assays. The ChIP kit (Millipore) was
employed according to the manufacturer’s instructions. Briefly, cells (1 × 107 per
assay) were bathed in 1% formaldehyde at 25 °C for 10min for cross-linking of
proteins and DNA and then lysed in sodium dodecyl sulfate buffer containing
protease inhibitors. DNA was sheared by sonication using a Sonic Dismembrator
Model 500 (Fisher Scientific, Pittsburgh, PA, USA). Immunoprecipitation was carried
out by incubation with 1 µg of anti-FLAG (M185-3L, MBL), anti-NANOG (A300-
397A, Bethyl Laboratories) antibodies or rabbit IgG (Millipore) for 16 h. For qChIP
assay, immunoprecipitated DNA was quantified by real-time qPCR using following
primer sets; 5’-TGGCCAAAATATCCGAAAATTCCC-3’ (forward) and 5’-CAG-
TAGCTGGGACGAGCGTG-3’ (reverse). Each sample was assayed in triplicate, and
the amount of precipitated DNA was calculated as the percentage of input sample.
CTL-mediated apoptosis assay. CaSki and MDA-MB231 cells were labeled with
CFSE (10 μM,Molecular Probes, Eugene, OR) in DMEM supplemented with 0.1% FBS.
The CFSE-labeled CaSki cells were pulsed with MART1 peptide (10 μgmL−1) for 1 h.
The CFSE-labeled MDA-MB231 cells and CaSki cells were mixed with cognate MART-
1 or control noncognate NY-ESO1-specific CD8+ CTLs at a 1:1 ratio and incubated for
4 h at 37 °C. Cells were stained for active caspase-3 as an index of apoptosis and
examined by flow cytometry as shown gating strategy in Supplementary Fig. 21.
Granzyme B-mediated apoptosis assay. Recombinant human granzyme B
(Enzo Life Sciences) was mixed with BioPorter Reagent (Sigma-Aldrich) at 25 °C
for 5 min. Tumor cells were mixed with BioPorter–granzyme B complexes for 4 h
at 37 °C. Cells were stained for active caspase-3 as an index of apoptosis and
examined by flow cytometry.
Trypan blue exclusion assay. For determining cell viability, trypan blue exclusion
assay was performed. Briefly, cells were seeded at 1 × 105 cells per well in 12-well
plates 1 day prior to the assay. Chemical reagents were treated at the concentra-
tions indicated in figures. After 24 h, cells were detached and stained with 0.4%
trypan blue. Unstained cells were counted using a hemocytometer. Data are
expressed as percentages of unstained cells compared with control cells not exposed
to the chemical reagents.
γ-irradiation-mediated viability assay. Cells were subjected to irradiation with a
range of doses (0, 2, 4, 8, or 10 Gy) with a 137Cs radiator at a rate of 2.01 Gy/min
and seeded into tissue culture plates. After culture for 96 h, viability was measured
by trypan blue exclusion assay or active caspase-3 assay. After treatment of
AUY922, cells were irradiated at 2 Gy.
Tumor sphere-forming assay. Cells were plated at 1 × 103 cells per well in six-
well, super-low adherence vessels (Corning, Lowell, MA) containing serum-free
DMEM-F12 (Thermo Scientific, Waltham, MA) supplemented with epidermal
growth factor (20 ng mL−1), basic fibroblast growth factor (20 ng mL−1), and 1 ×
B27. Medium was replaced every 3 days to replenish nutrients. Colonies more than
50 μm in diameter were counted under a microscope.
In vivo limiting dilution transplantation assay. To assess the role of HSP90A in
tumor-initiating property of immune-edited CaSki P3 cells, we performed in vivo-
limiting dilution transplantation assay using CaSki P3 cells stably transfected with
empty vector (no insert), shHSP90AA1#1, or shHSP90AA1#2. Limiting doses of
the tumor cells were subcutaneously injected into NOD/SCID mice. Six weeks after
injection, mice were scored for the presence of palpable tumors. The frequency of
tumorigenic cells and the 95% confidence interval were calculated using extreme
limiting dilution analysis (ELDA)59.
Luciferase assay. To determine the promoter activity of HSP90AA1, luciferase
assay was performed. Briefly, the reporter construct, pGL3 basic, pGL3-HSP90AA1
WT, or pGL3-HSP90AA1 MUT together with pCMV-β-Gal, an internal control
for transfection efficiency, were co-transfected into HEK293 cells using Lipo-
fectamine 2000 (Invitrogen). After 24 h, cells were washed with PBS and lysed with
Cell Culture Lysis Reagent (Promega). Luciferase activity was measured with a
Turner Biosystems TD-20/20 luminometer after addition of 40 µl of luciferase
assay reagent (Promega). Relative luciferase activity was normalized with the β-
galactosidase activity in the cell lysate and calculated as an average of three inde-
pendent experiments.
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Immunoprecipitation. HEK293 cells were transfected with pME18-myc/TCL1 for
24 h, and were lysed in NP40 lysis buffer (50 mM Tris–HCl, pH 8.0, 5 mM EDTA,
150 mM NaCl, 1% NP-40, 1 mM PMSF) containing protease inhibitor. Immuno-
precipitation was carried out by incubation with 1 μg of anti-Myc antibody or
mouse IgG for 16 h. The bound proteins were eluted by boiling in SDS sample
buffer and were immunoblotted using anti-HSP90A antibody.
In vivo ubiquitination assay. HA-tagged ubiquitin together with pME18-myc/
TCL1 were co-transfected into HEK293 cells using Lipofectamine 2000 (Invitro-
gen). After 24 h, the cells were treated with 10 μM of MG132 for 8 h and lysed by
incubation with two volumes of TBS containing 2% SDS at 95 °C for 10 min. After
adding eight volumes of TBS containing 1% Triton X-100, lysates were sonicated
and then immunoprecipitated with anti-Myc antibody coupled to TrueBlot anti-
mouse Ig IP beads. The beads were washed with TBS, eluted by boiling in SDS
sample buffer and immunoblotted using anti-HA antibody.
Tissue samples and immunohistochemistry. Tissue microarrays (TMAs) con-
taining four 1.0-mm-diameter cores retrieved from 483 formalin-fixed, paraffin-
embedded tumor specimens, and matched nonadjacent normal specimens, were
previously described16. The study subjects were compromised of 169 cervical
cancers and 314 cervical intraepithelial neoplasia (CIN) patients who underwent
surgical resection in Gangnam Severance Hospital between 1996 and 2010. Some of
the paraffin blocks were provided by the Korea Gynecologic Cancer Bank through
Bio & Medical Technology Development Program of the Ministry of Education,
Science and Technology, Korea (NRF-2017M3A9B8069610). Tissue samples were
collected from patients who had signed informed consent form. This study was
approved by the Institutional Review Board of Gangnam Severance Hospital
(Seoul, South Korea), and all procedures were conducted in accordance with the
guidelines of the Declaration of Helsinki.
The TMA sections were deparaffinized by xylene and then rehydrated through a
graded ethanol series. Antigen retrieval was performed in heat-activated antigen
retrieval pH 6.0 (Dako, Carpinteria, CA). Endogenous peroxidase activity was
quenched with 3% H2O2 for 10 min. The sections were incubated for 30 min with
mouse monoclonal anti-HSP90A antibodies (Abcamz, Cambridge, MA; Clone
4F10) at 1:4000 dilutions, followed by a standard ABC protocol using EnVision+
Dual Link System-HRP (Dako). The reactions were visualized using 3,3-
diaminobenzadine substrate for 10 min and lightly counter-stained with
hematoxylin. Negative controls including immunoglobulin G (IgG) and omission
of the primary antibody were concurrently performed, and the TMA included
appropriate positive control tissues. NANOG protein expression was previously
evaluated in the same cohort16.
For digital image analysis, all stained slides were scanned using the
NanoZoomer 2.0 HT (Hamamatsu Photonics K.K., Japan) at ×40 objective
magnification (0.23 μm per pixel resolution). The images were analyzed using
Visiopharm software v6.2.0.2089 (Visiopharm, Hørsholm, Denmark). Tumor
nuclei were defined after training the system. Cytoplasm was further defined by
outlining the defined nucleus. DAB intensity was obtained by using a predefined
algorithm ranging from 0 (no signal) to 300 (fully saturated signal), as described
previously60.
Bioinformatic analyses from published clinical database. RNA-seq datasets
from three cancer types (cholangiocarcinoma, testicular germ cell tumors, and
uveal melanoma) at the Cancer Genome Atlas (TCGA) portal (https://tcga-data.
nci.nih.gov/tcga/)61 were used to calculate a correlation coefficient (r) between
NANOG and HSP90AA1 expressions. To investigate the clinical relevance in
patients treated with anti-PD-1 therapy, we used the published datasets
(GSE91061)29. RNA-seq read counts were log2 normalized, and unbiased median
gene expression value cutoffs were applied for the analysis of high/low expression
subgroups and their potential associations with overall disease outcome (days to
death or last follow-up).
To explore the gene sets transcriptionally regulated by NANOG and IRF8,
we analyzed DEGs using TF-LOF Expression from gene expression omnibus
(GEO)62. Briefly, DEGs were then identified for NR versus R to anti-PD-1 therapy
at thresholds of FDR < 0.05, 1.5FC. The unbiased lists of significantly up-regulated
and down-regulated genes were used to conduct upstream regulatory analysis
using TF-LOF expression analysis. A preliminary NANOG-responsive genes was
derived using the TF analysis and validated followed by filtering to overlap genes
that have been previously identified as responding to NANOG34–38. The
expression of multi-genes was calculated by averaging of the included genes for
the NANOG-responsive genes (six-gene: FGFBP1, SPESP1, HMGA2, PERP,
FGF1, and DKK1) and IRF8-responsive genes (24-gene: CD74, CIITA, LY86,
ZBTB32, FLT3LG, DAPP1, RNASE4, TAPBPL, LSP1, CTSS, SOCS1, HLA-DMB,
ELF4, KYNU, UCP2, TLR9, BLNK, HLA-DRA, LPXN, IRF5, CD37, SLC15A3,
MS4A1 and GPR18) as described previously63.
Tumor treatment experiments. NOD/SCID mice were inoculated subcutaneously
with 2 × 106 MDA-MB231 P3 cells per mouse. Seven days following tumor challenge,
AUY922 (0.05mg kg−1) or PBS was treated via intraperitoneal route. Following day
after AUY922 treatment, mice received adoptive transfer with 2 × 106 MART-1-
specific CTLs. This treatment regimen was repeated for three cycles. Mice were
monitored for tumor burden and survival for 21 and 40 days after challenge,
respectively. C57BL/6 mice were inoculated subcutaneously with 1 × 106 tumor cells
per mouse. Between 5 and 13 days following tumor challenge, AUY922 (0.05mg kg
−1) or PBS was treated via intraperitoneal route. Following day after AUY922
treatment, mice administered anti-PD-1 (BioXcell, NH, USA) or isotype antibody
control that was administrated every 3 days at a dose of 200 μg per mice in accordance
with the schedule described in Fig. 8a and Supplementary Fig. 20a. This treatment
regimen was repeated for three cycles. Mice were monitored for tumor burden and
survival for 20 and 40 days after challenge, respectively.
Immune cell tumor infiltration. Treated C57BL/6 mice were sacrificed on day 15
following tumor inoculation and tumors were harvested. Tumors were dissected
into fragments by cutting, dissociated by a cell strainer. Cell suspensions were
stained for intracellular and extracellular protein markers of interest. Stained
samples were assessed on a flow cytometer (BD biosciences, San, USA) along with
CellQuest Pro software. Staining antibodies were as follows: anti-CD3 (BD bios-
ciences, San, USA), anti-CD8 (BD biosciences, San, USA), anti-granzyme B (BD
biosciences, San, USA), and anti-IFN-γ (BD biosciences, San, USA).
Analysis of generation of antigen-specific T cells. To investigate the generation
of tumor antigen-specific CD8+ T cells, treated C57BL/6 mice were sacrificed on
day 15 following tumor inoculation and tumors, drain lymph nodes and spleens
were harvested and incubated with either DMSO or gp100 peptide
(KVPRNQDWL) at 1 μg mL−1 for 24 h and stained with anti-CD8. Cell fixation
and permeabilization were conducted thereafter with the CytoFix/CytopermTM kit
(BD biosciences, San, USA), followed by washing with cold PBS and labeling with
anti-IFN-γ. The flow cytometer along with CellQuest Pro software was used to
quantify the number of antigen-specific IFN-γ+, CD8+ T cells.
Statistical analysis. All data are representative of at least three separate experi-
ments. Statistical differences were calculated by either Student’s t-test (two-tailed,
unpaired), one-way ANOVA, or two-way ANOVA using GraphPad Prism software.
For tissue samples and immunohistochemistry, statistical analyses were performed
using IBM SPSS statistics version 21 (IBM Corporation, Armonk, NY). The sta-
tistical significance of the differences in the protein expressions in the different
groups was calculated by the Mann–Whitney U test. Chi-square test was used to
assess associations between protein expressions and tumor size. Spearman’s rank
correlation analysis was used to evaluate the association between protein markers.
Survival curves were calculated using the Kaplan–Meier method and the difference
between the survival curves was calculated by the log-rank test. A Cox proportional
hazards model was created to identify independent predictors of survival. Results
with two-tailed p-values < 0.05 were considered statistically significant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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